{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:06:01Z","timestamp":1768867561232,"version":"3.49.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.diabres.2023.110726","type":"journal-article","created":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T02:00:10Z","timestamp":1684548010000},"page":"110726","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Has the time come to step up to \u201ctriple therapy\u201d for the treatment of diabetic kidney disease?"],"prefix":"10.1016","volume":"201","author":[{"given":"Dimitrios","family":"Patoulias","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Djordje S.","family":"Popovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaos","family":"Fragakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manfredi","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.diabres.2023.110726_b0005","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1007\/s00125-018-4654-7","article-title":"Development of SGLT1 and SGLT2 inhibitors","volume":"61","author":"Rieg","year":"2018","journal-title":"Diabetologia"},{"issue":"12","key":"10.1016\/j.diabres.2023.110726_b0010","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1007\/s00125-022-05787-2","article-title":"Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"65","author":"Davies","year":"2022","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabres.2023.110726_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.cardfail.2023.02.012","article-title":"Time to Quadruple Guideline-Directed Medical Therapy as a Key Performance Measure for Heart Failure","author":"Shahid","year":"2023","journal-title":"J Card Fail."},{"issue":"12","key":"10.1016\/j.diabres.2023.110726_b0020","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.2215\/CJN.11491116","article-title":"Diabetic Kidney Disease: Challenges, Progress, and Possibilities","volume":"12","author":"Alicic","year":"2017","journal-title":"CJASN"},{"issue":"9854","key":"10.1016\/j.diabres.2023.110726_b0025","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/S0140-6736(12)61350-6","article-title":"Chronic Kidney Disease Prognosis Consortium. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis","volume":"380","author":"Fox","year":"2012","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.diabres.2023.110726_b0030","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1159\/000489913","article-title":"Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on All-Cause Mortality and Renal Outcomes in Patients with Diabetes and Albuminuria: a Systematic Review and Meta-Analysis","volume":"43","author":"Wang","year":"2018","journal-title":"Kidney Blood Press Res"},{"issue":"8","key":"10.1016\/j.diabres.2023.110726_b0035","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/ajh.2008.206","article-title":"Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis","volume":"21","author":"Sarafidis","year":"2008","journal-title":"Am J Hypertens"},{"issue":"5","key":"10.1016\/j.diabres.2023.110726_b0040","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1053\/j.ajkd.2012.07.005","article-title":"KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update","volume":"60","author":"National Kidney Foundation","year":"2012","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"10.1016\/j.diabres.2023.110726_b0045","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/j.clinthera.2015.05.508","article-title":"Spironolactone Add-on for Preventing or Slowing the Progression of Diabetic Nephropathy: A Meta-analysis","volume":"37","author":"Hou","year":"2015","journal-title":"Clin Ther"},{"issue":"3","key":"10.1016\/j.diabres.2023.110726_b0050","doi-asserted-by":"crossref","first-page":"e0265642","DOI":"10.1371\/journal.pone.0265642","article-title":"Efficacy and safety of eplerenone treatment for patients with diabetic nephropathy: A meta-analysis","volume":"17","author":"Hu","year":"2022","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.diabres.2023.110726_b0055","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/jdi.12629","article-title":"Effects of mineralocorticoid receptor antagonists on the progression of diabetic nephropathy","volume":"8","author":"Sun","year":"2017","journal-title":"J Diabetes Investig"},{"issue":"23","key":"10.1016\/j.diabres.2023.110726_b0060","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.diabres.2023.110726_b0065","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.diabres.2023.110726_b0070","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.2337\/dc22-0294","article-title":"FIDELIO-DKD and FIGARO-DKD Investigators. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis","volume":"45","author":"Rossing","year":"2022","journal-title":"Diabetes Care"},{"issue":"24","key":"10.1016\/j.diabres.2023.110726_b0075","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.diabres.2023.110726_b0080","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.diabres.2023.110726_b0085","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients with Chronic Kidney Disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.diabres.2023.110726_b0090","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in Patients with Chronic Kidney Disease","volume":"388","author":"The EMPA-KIDNEY Collaborative Group","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2023.110726_b0095","unstructured":"Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022 Nov 19;400(10365):1788-1801. doi: 10.1016\/S0140-6736(22)02074-8. Epub 2022 Nov 6. PMID: 36351458; PMCID: PMC7613836."},{"key":"10.1016\/j.diabres.2023.110726_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2022.110161","article-title":"Cardiovascular and kidney outcomes of combination therapy with sodium-glucose cotransporter-2 inhibitors and mineralocorticoid receptor antagonists in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis","volume":"194","author":"Tsukamoto","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"issue":"5","key":"10.1016\/j.diabres.2023.110726_b0105","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1111\/dom.14976","article-title":"Effects of sodium\u2010glucose cotransporter 2 inhibitors, mineralocorticoid receptor antagonists, and their combination on albuminuria in diabetic patients","volume":"25","author":"Morita","year":"2023","journal-title":"Diabetes Obesity Metabolism"},{"key":"10.1016\/j.diabres.2023.110726_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2023.110592","article-title":"Efficacy and safety of drugs for people with type 2 diabetes mellitus and chronic kidney disease on kidney and cardiovascular outcomes: A systematic review and network meta-analysis of randomized controlled trials","volume":"198","author":"Yang","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"issue":"6","key":"10.1016\/j.diabres.2023.110726_b0115","doi-asserted-by":"crossref","first-page":"108456","DOI":"10.1016\/j.jdiacomp.2023.108456","article-title":"Efficacy and safety of sodium glucose cotransporter 2 inhibitors plus standard care in diabetic kidney disease: A systematic review and meta-analysis","volume":"37","author":"Woodhams","year":"2023","journal-title":"J Diabetes Complications"},{"issue":"2","key":"10.1016\/j.diabres.2023.110726_b0120","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3390\/biomedicines11020291","article-title":"Advances in the Pharmacological Management of Diabetic Nephropathy: A 2022 International Update","volume":"11","author":"Giglio","year":"2023","journal-title":"Biomedicines"},{"issue":"9","key":"10.1016\/j.diabres.2023.110726_b0125","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1080\/14740338.2022.2130889","article-title":"Efficacy and safety of finerenone for treatment of diabetic kidney disease: current knowledge and future perspective","volume":"21","author":"Marzolla","year":"2022","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"10.1016\/j.diabres.2023.110726_b0130","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41581-021-00522-3","article-title":"Expanding the therapy options for diabetic kidney disease","volume":"18","author":"Fioretto","year":"2022","journal-title":"Nat Rev Nephrol"},{"issue":"4","key":"10.1016\/j.diabres.2023.110726_b0135","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1093\/ndt\/gfac198","article-title":"Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE)","volume":"38","author":"Green","year":"2023","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1016\/j.diabres.2023.110726_b0140","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/jdi.13116","article-title":"Prevalence of albuminuria and renal dysfunction, and related clinical factors in Japanese patients with diabetes: The Japan Diabetes Complication and its Prevention prospective study 5","volume":"11","author":"Shikata","year":"2020","journal-title":"J Diabetes Investig"},{"issue":"1","key":"10.1016\/j.diabres.2023.110726_b0145","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/1753-0407.13230","article-title":"A study on the status of normoalbuminuric renal insufficiency among type 2 diabetes mellitus patients: A multicenter study based on a Chinese population","volume":"14","author":"Jia","year":"2022","journal-title":"J Diabetes"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822723004898?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822723004898?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:25:09Z","timestamp":1759173909000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822723004898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":29,"alternative-id":["S0168822723004898"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2023.110726","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Has the time come to step up to \u201ctriple therapy\u201d for the treatment of diabetic kidney disease?","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2023.110726","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110726"}}